Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Resolution of Cellular Heterogeneity in Human Prostate Cancers: Implications for Diagnosis and Treatment.

Maitland NJ, Frame FM, Rane JK, Erb HH, Packer JR, Archer LK, Pellacani D.

Adv Exp Med Biol. 2019;1164:207-224. doi: 10.1007/978-3-030-22254-3_16. Review.

PMID:
31576551
2.

Spatial Intratumor Genomic Heterogeneity within Localized Prostate Cancer Revealed by Single-nucleus Sequencing.

Su F, Zhang W, Zhang D, Zhang Y, Pang C, Huang Y, Wang M, Cui L, He L, Zhang J, Zou L, Zhang J, Li W, Li L, Shao J, Ma J, Xiao F, Liu M.

Eur Urol. 2018 Nov;74(5):551-559. doi: 10.1016/j.eururo.2018.06.005. Epub 2018 Jun 23.

PMID:
29941308
3.

Italian cancer figures--Report 2015: The burden of rare cancers in Italy.

AIRTUM Working Group, Busco S, Buzzoni C, Mallone S, Trama A, Castaing M, Bella F, Amodio R, Bizzoco S, Cassetti T, Cirilli C, Cusimano R, De Angelis R, Fusco M, Gatta G, Gennaro V, Giacomin A, Giorgi Rossi P, Mangone L, Mannino S, Rossi S, Pierannunzio D, Tavilla A, Tognazzo S, Tumino R, Vicentini M, Vitale MF, Crocetti E, Dal Maso L.

Epidemiol Prev. 2016 Jan-Feb;40(1 Suppl 2):1-120. doi: 10.19191/EP16.1S2.P001.035. Erratum in: Epidemiol Prev. 2016 Mar-Apr;40(2):83.

4.

The complexity of prostate cancer: genomic alterations and heterogeneity.

Boyd LK, Mao X, Lu YJ.

Nat Rev Urol. 2012 Nov;9(11):652-64. doi: 10.1038/nrurol.2012.185. Review.

PMID:
23132303
5.

More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.

Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.

Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7.

PMID:
30843003
6.

Unbiased data mining identifies cell cycle transcripts that predict non-indolent Gleason score 7 prostate cancer.

Johnston WL, Catton CN, Swallow CJ.

BMC Urol. 2019 Jan 7;19(1):4. doi: 10.1186/s12894-018-0433-5.

7.

Multifocal Primary Prostate Cancer Exhibits High Degree of Genomic Heterogeneity.

Løvf M, Zhao S, Axcrona U, Johannessen B, Bakken AC, Carm KT, Hoff AM, Myklebost O, Meza-Zepeda LA, Lie AK, Axcrona K, Lothe RA, Skotheim RI.

Eur Urol. 2019 Mar;75(3):498-505. doi: 10.1016/j.eururo.2018.08.009. Epub 2018 Sep 1.

PMID:
30181068
8.

Exome sequencing of prostate cancer supports the hypothesis of independent tumour origins.

Lindberg J, Klevebring D, Liu W, Neiman M, Xu J, Wiklund P, Wiklund F, Mills IG, Egevad L, Grönberg H.

Eur Urol. 2013 Feb;63(2):347-53. doi: 10.1016/j.eururo.2012.03.050. Epub 2012 Mar 31.

PMID:
22502944
9.

Regional biases in mutation screening due to intratumoural heterogeneity of prostate cancer.

Kim TM, Jung SH, Baek IP, Lee SH, Choi YJ, Lee JY, Chung YJ, Lee SH.

J Pathol. 2014 Aug;233(4):425-35. doi: 10.1002/path.4380.

PMID:
24870262
10.

Intratumoral and Intertumoral Genomic Heterogeneity of Multifocal Localized Prostate Cancer Impacts Molecular Classifications and Genomic Prognosticators.

Wei L, Wang J, Lampert E, Schlanger S, DePriest AD, Hu Q, Gomez EC, Murakam M, Glenn ST, Conroy J, Morrison C, Azabdaftari G, Mohler JL, Liu S, Heemers HV.

Eur Urol. 2017 Feb;71(2):183-192. doi: 10.1016/j.eururo.2016.07.008. Epub 2016 Jul 21.

11.

Intratumour heterogeneity in urologic cancers: from molecular evidence to clinical implications.

Gerlinger M, Catto JW, Orntoft TF, Real FX, Zwarthoff EC, Swanton C.

Eur Urol. 2015 Apr;67(4):729-37. doi: 10.1016/j.eururo.2014.04.014. Epub 2014 May 2. Review.

PMID:
24836153
12.

The diverse heterogeneity of molecular alterations in prostate cancer identified through next-generation sequencing.

Wyatt AW, Mo F, Wang Y, Collins CC.

Asian J Androl. 2013 May;15(3):301-8. doi: 10.1038/aja.2013.13. Epub 2013 Mar 18. Review.

13.

A three-marker FISH panel detects more genetic aberrations of AR, PTEN and TMPRSS2/ERG in castration-resistant or metastatic prostate cancers than in primary prostate tumors.

Qu X, Randhawa G, Friedman C, Kurland BF, Glaskova L, Coleman I, Mostaghel E, Higano CS, Porter C, Vessella R, Nelson PS, Fang M.

PLoS One. 2013 Sep 30;8(9):e74671. doi: 10.1371/journal.pone.0074671. eCollection 2013.

14.

Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis.

Risbridger GP, Taylor RA, Clouston D, Sliwinski A, Thorne H, Hunter S, Li J, Mitchell G, Murphy D, Frydenberg M, Pook D, Pedersen J, Toivanen R, Wang H, Papargiris M, Lawrence MG, Bolton DM.

Eur Urol. 2015 Mar;67(3):496-503. doi: 10.1016/j.eururo.2014.08.007. Epub 2014 Aug 22.

PMID:
25154392
15.

Image-based computational quantification and visualization of genetic alterations and tumour heterogeneity.

Zhong Q, Rüschoff JH, Guo T, Gabrani M, Schüffler PJ, Rechsteiner M, Liu Y, Fuchs TJ, Rupp NJ, Fankhauser C, Buhmann JM, Perner S, Poyet C, Blattner M, Soldini D, Moch H, Rubin MA, Noske A, Rüschoff J, Haffner MC, Jochum W, Wild PJ.

Sci Rep. 2016 Apr 7;6:24146. doi: 10.1038/srep24146.

16.

Heterogeneity of d-glucuronyl C5-epimerase expression and epigenetic regulation in prostate cancer.

Prudnikova TY, Soulitzis N, Kutsenko OS, Mostovich LA, Haraldson K, Ernberg I, Kashuba VI, Spandidos DA, Zabarovsky ER, Grigorieva EV.

Cancer Med. 2013 Oct;2(5):654-61. doi: 10.1002/cam4.108. Epub 2013 Aug 5.

17.

The Heterogeneity of Prostate Cancer: A Practical Approach.

Tolkach Y, Kristiansen G.

Pathobiology. 2018;85(1-2):108-116. doi: 10.1159/000477852. Epub 2018 Jan 31.

18.
19.

Genome-wide investigation of multifocal and unifocal prostate cancer-are they genetically different?

Ibeawuchi C, Schmidt H, Voss R, Titze U, Abbas M, Neumann J, Eltze E, Hoogland AM, Jenster G, Brandt B, Semjonow A.

Int J Mol Sci. 2013 Jun 3;14(6):11816-29. doi: 10.3390/ijms140611816.

20.

Heat shock protein expression independently predicts clinical outcome in prostate cancer.

Cornford PA, Dodson AR, Parsons KF, Desmond AD, Woolfenden A, Fordham M, Neoptolemos JP, Ke Y, Foster CS.

Cancer Res. 2000 Dec 15;60(24):7099-105.

Supplemental Content

Support Center